KIR3DL1 and neoplasm: Here, we show that the repertoire of KIR/KIR-ligands that an individual inherits is associated with their clinical response to BEMPEG plus nivolumab treatment; consistent with a role for NK cells in the anti-tumor efficacy of this combination therapy.